全文获取类型
收费全文 | 574篇 |
免费 | 32篇 |
国内免费 | 2篇 |
专业分类
耳鼻咽喉 | 2篇 |
儿科学 | 55篇 |
妇产科学 | 4篇 |
基础医学 | 73篇 |
口腔科学 | 11篇 |
临床医学 | 76篇 |
内科学 | 155篇 |
皮肤病学 | 21篇 |
神经病学 | 4篇 |
特种医学 | 139篇 |
外科学 | 15篇 |
综合类 | 9篇 |
预防医学 | 8篇 |
眼科学 | 4篇 |
药学 | 16篇 |
肿瘤学 | 16篇 |
出版年
2022年 | 3篇 |
2021年 | 9篇 |
2020年 | 2篇 |
2019年 | 3篇 |
2018年 | 7篇 |
2017年 | 2篇 |
2016年 | 5篇 |
2015年 | 10篇 |
2014年 | 12篇 |
2013年 | 15篇 |
2012年 | 8篇 |
2011年 | 15篇 |
2010年 | 26篇 |
2009年 | 20篇 |
2008年 | 9篇 |
2007年 | 8篇 |
2006年 | 10篇 |
2005年 | 11篇 |
2004年 | 7篇 |
2003年 | 11篇 |
2002年 | 6篇 |
2001年 | 4篇 |
2000年 | 2篇 |
1999年 | 3篇 |
1998年 | 35篇 |
1997年 | 46篇 |
1996年 | 45篇 |
1995年 | 36篇 |
1994年 | 19篇 |
1993年 | 22篇 |
1992年 | 6篇 |
1991年 | 11篇 |
1990年 | 6篇 |
1989年 | 17篇 |
1988年 | 27篇 |
1987年 | 21篇 |
1986年 | 23篇 |
1985年 | 13篇 |
1984年 | 5篇 |
1983年 | 5篇 |
1982年 | 5篇 |
1981年 | 14篇 |
1980年 | 6篇 |
1979年 | 5篇 |
1978年 | 8篇 |
1977年 | 9篇 |
1976年 | 5篇 |
1975年 | 9篇 |
1974年 | 1篇 |
1942年 | 1篇 |
排序方式: 共有608条查询结果,搜索用时 15 毫秒
241.
242.
SUMMARY Cryptorchidism occurs in about 1% of boys, but has a raised incidence in those with deficiencies of androgen function. Greater knowledge of fetal-maternal endocrinology and related experimental work has provided evidence that fetal testicular endocrine function is vital in descent of the gonad. The therapeutic use of hCG has, however, been disappointing, and its role is confined to helping to distinguish the retractile from the undescended testis. Cryptorchidism is commonly associated with congenital pathological defects such as ductal abnormalities, and others (including interstitial fibrosis and a reduction in germ cells) develop after 1-2 years, while later these patients are at greater risk of carcinoma in situ and germ cell cancer. The demonstration of the early pathological changes has recently dictated much earlier surgical correction, but long-term follow-up is needed to prove clinical benefit from this practice. 相似文献
243.
Continuous infusion of the anti-CD22 immunotoxin IgG-RFB4-SMPT-dgA in patients with B-cell lymphoma: a phase I study 总被引:3,自引:1,他引:2
Sausville EA; Headlee D; Stetler-Stevenson M; Jaffe ES; Solomon D; Figg WD; Herdt J; Kopp WC; Rager H; Steinberg SM 《Blood》1995,85(12):3457-3465
IgG-RFB4-SMPT-dgA consists of deglycosylated ricin A chain (dgA) coupled to the monoclonal antihuman CD22 antibody, RFB4. This study determined the maximally tolerated dose (MTD) of this immunotoxin (IT) administered as a continuous 8-day infusion to 18 patients with B-cell lymphoma (30% CD22+ tumor cells) over 8 days. The MTD was 19.2 mg/m2/192 h (maximum toxicity grade 1), with vascular leak syndrome (VLS) as dose-limiting toxicity (DLT) at 28.8 mg/m2/192 h (grades 3 through 5 in 7 of 11 patients). Predictors of severe VLS included serum IT concentrations greater than 1,000 ng/mL and the absence of circulating tumor cells. Decreased urine sodium excreted in 24 hours provided evidence for mild VLS without notable changes in serum albumin. Four partial responses, 3 minor responses, 6 stable disease, and 3 progression of disease were observed. The mean maximal serum concentration (Cmax) in initial courses at the MTD (19.2 mg/m2) was 443 +/- 144 ng/mL (n = 3; range, 326 to 604). At 28.8 mg/m2/192 h, the Cmax was highly variable (n = 11; mean, 1,102 +/- 702; range, 9.6 to 2,032 ng/mL). Human antimouse or antiricin antibodies developed in 6 of 16 (37.5%) patients after one course of IT. However, 10 eligible patients received multiple courses of IT. Changes in serum cytokines and cytokine receptors did not correlate with toxicity but decreased soluble interleukin-2 receptor concentrations correlated with clinical response. Comparison to a prior study with the same IT administered by intermittent bolus infusions (Amlot et al, Blood 82:2624, 1993) suggests similar clinical response, toxicity, and immunogenicity. 相似文献
244.
Correlative morphologic and molecular genetic analysis demonstrates three distinct categories of posttransplantation lymphoproliferative disorders 总被引:36,自引:11,他引:25
Knowles DM; Cesarman E; Chadburn A; Frizzera G; Chen J; Rose EA; Michler RE 《Blood》1995,85(2):552-565
The posttransplantation lymphoproliferative disorders (PT-LPDs) are a morphologically heterogeneous group of Epstein-Barr virus (EBV)-driven lymphoid proliferations of varying clonal composition. Some PT-LPDs regress after a reduction in immunosuppression, while others progress in spite of aggressive therapy. Previously defined morphologic categories do not correlate with clonality, and neither morphology nor clonality has reliably predicted the clinical behavior of PT-LPDs. We investigated 28 PT-LPD lesions occurring in 22 patients for activating alterations involving the bcl-1, bcl-2, c-myc, and H-, K- and N-ras proto-oncogenes and for mutations involving the p53 tumor suppressor gene. We correlated the results of these studies with the morphology of the lesions, their clonality based on Ig heavy and light chain gene rearrangement analysis, and the presence and clonality of EBV infection. We found that the PT-LPDs are divisible into three distinct categories as follows: (1) plasmacytic hyperplasia: most commonly arise in the oropharynx or lymph nodes, are nearly always polyclonal, usually contain multiple EBV infection events or only a minor cell population infected by a single form of EBV, and lack oncogene and tumor suppressor gene alterations; (2) polymorphic B-cell hyperplasia and polymorphic B-cell lymphoma: may arise in lymph nodes or various extranodal sites, are nearly always monoclonal, usually contain a single form of EBV, and lack oncogene and tumor suppressor gene alterations; and (3) immunoblastic lymphoma or multiple myeloma: present with widely disseminated disease, are monoclonal, contain a single form of EBV, and contain alterations of one or more oncogene or tumor suppressor genes (N-ras gene codon 61 point mutation, p53 gene mutation, or c-myc gene rearrangement). The PT-LPDs are divisible into three categories exhibiting distinct morphologic and molecular genetic characteristics. Alterations involving the N-ras and c-myc proto- oncogenes and the p53 tumor suppressor gene may play an important role in the development and/or progression of the PT-LPDs. 相似文献
245.
AK Gupta†‡ A Adamiak‡ EA Cooper‡ 《Journal of the European Academy of Dermatology and Venereology》2003,17(6):627-640
Terbinafine is an allylamine antifungal agent that has been effective and safe in the treatment of superficial and some deep mycotic infections in adults. An increasing amount of data is available where terbinafine has been used in the paediatric population to treat superficial fungal infections, in particular tinea capitis. The data suggest that terbinafine is effective and safe using treatment regimens that involve short duration therapy, leading to an increased compliance and providing a cost-effective means of treating paediatric superficial fungal infections such as tinea capitis. Terbinafine has been approved for the treatment of tinea capitis in many countries worldwide, and provides good efficacy rates for Trichophyton tinea capitis using shorter regimens than the gold standard griseofulvin. The adverse events profile for children is similar to that in adults with few adverse effects associated with its use. The evidence favours the use of terbinafine in the treatment of superficial infections in children. 相似文献
246.
247.
248.
249.
250.